{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004423","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.226545+00:00","generated_at":"2026-06-20T17:44:02.854953+00:00","sec_items":["5.02","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted","bullets":["Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.","Submitted New Drug Application to US FDA and Marketing Authorization Application to EMA for pegcetacoplan.","Appointed Dr. Caroline Baumal as Chief Medical Officer effective Q1 2023.","Completed enrollment in Phase 2 ALS study; progressed late-stage pipeline with partner Sobi.","Deployed ~100 field-based employees mid-2022 for US commercial launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004423","json":"https://secwatch.observer/filing/0001193125-23-004423.json","markdown":"https://secwatch.observer/filing/0001193125-23-004423.md","text":"https://secwatch.observer/filing/0001193125-23-004423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/0001193125-23-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/d436376d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:44:02.854953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6623b35dbbfc7c6861756fb330b7bb3f6930266","claim":"Apellis Pharmaceuticals, Inc. reported FY 2022 results: revenue $65 million.","evidence_excerpt":"Caroline Baumal as Chief Medical Officer (effective Q1 2023) ~$65 million1 in U.S. net product sales Submitted sNDA for PRINCE & 48-week PEGASUS data Submitted sNDA for EMPAVELI injector Completed >800 patient years of systemic dosing2 Progressed late-stage clinical studies with partner Sobi Advanced early-stage","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/0001193125-23-004423-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2022"},{"label":"Revenue","value":"$65 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}